SLC5A2 and fatty liver disease: Some studies on SGLT2 inhibitor therapy in patients with or without T2DM have reported no significant correlation between changes in body mass index (BMI) and liver steatosis parameters, specifically the controlled attenuation parameter (CAP), an ultrasound method for measuring hepatic fat content.